newsfilter
← Latest News
GlobeNewswire·

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

  • LifeMD, Inc. (NASDAQ: LFMD) launched Novo Nordisk's first GLP-1 subscription program for Wegovy® (semaglutide) on March 31, 2026.
  • The program offers structured pricing to eligible patients, providing up to $1,200 in annual savings for injectable formulations & $600 for oral therapy.
  • Justin Schreiber, LifeMD's Chairman & CEO, stated the initiative deepens the collaboration with Novo Nordisk to make branded obesity treatment more accessible & affordable.
  • The partnership has expanded since 2025 to include injectable & oral Wegovy® & Ozempic®, with LifeMD recognized as a telehealth provider on both NovoCare® & Wegovy® websites.
  • Patients gain access to virtual visits across all 50 states, ongoing clinical oversight, nationwide diagnostic testing, & simplified billing.
  • The subscription program is available to eligible patients at https://lifemd.com/weight-management/.